Literature DB >> 5166612

Modulation of function of the activated first component of complement by a fragment derived from serum. I. Effect on early components of complement.

I Gigli, A P Kaplan, K F Austen.   

Abstract

An activity designated Kf can be separated from human serum and shown to give a 100-300% enhancement in the hemolytic activity of fully activated, fractionated C1. The enhancement of C1 activity is not because of activation of precursor C1 and it is not attributable to an effect on C1 binding. EAC42 or EAC4 intermediates interacted with C1Kf exhibit a greater T(max) and shorter Z(max) than when such intermediates are reacted with the same number of hemolytic units of C1. C3 consumption by the EAC1Kf42 intermediate greatly exceeds that of the EAC142 intermediate produced from the same EAC4 cells by comparable inputs of the other two complement components. Taken together, these findings suggest that Kf-treated C1 achieves more efficient utilization of C4 and C2 to create a larger number of 42 sites as appreciated on the intermediates by shorter T(max) and a greater Z(max), and an increased capacity to utilize C3. The capacity of Kf to enhance C1 upon introduction into whole serum of a patient with hereditary angioedema (HAE) in a manner comparable to its effect on fractionated C1 suggests that the effect of Kf may be pertinent to certain pathophysiologic conditions of man.

Entities:  

Mesh:

Substances:

Year:  1971        PMID: 5166612      PMCID: PMC2139103          DOI: 10.1084/jem.134.6.1466

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  25 in total

1.  A stoichiometric assay for the fourth component of complement in whole human serum using EAC'la-gp and functionally pure human second component.

Authors:  S Ruddy; K F Austen
Journal:  J Immunol       Date:  1967-12       Impact factor: 5.422

2.  Immune hemolysis: a simplified method for the preparation of EAC'4 with guinea pig or with human complement.

Authors:  T Borsos; H J Rapp
Journal:  J Immunol       Date:  1967-08       Impact factor: 5.422

3.  The stoichiometric measurement of the serum inhibition of the first component of complement by the inhibition of immune hemolysis.

Authors:  I Gigli; S Ruddy; K F Austen
Journal:  J Immunol       Date:  1968-06       Impact factor: 5.422

4.  C3 inactivator of man. I. Hemolytic measurement by the inactivation of cell-bound C3.

Authors:  S Ruddy; K F Austen
Journal:  J Immunol       Date:  1969-03       Impact factor: 5.422

5.  Hemolysin titration based on fixation of the activated first component of complement: evidence that one molecule of hemolysin suffices to sensitize an erythrocyte.

Authors:  T Borsos; H J Rapp
Journal:  J Immunol       Date:  1965-09       Impact factor: 5.422

6.  Activation of C'1 to C'1 esterase on gel filtration on Sephadex G-200. Studies on normal human serum, euglobulin and hereditary angioneurotic edema serum.

Authors:  A B Laurell; R Siboo
Journal:  Acta Pathol Microbiol Scand       Date:  1966

7.  Methods for the separation, purification and measurement of nine components of hemolytic complement in guinea-pig serum.

Authors:  R A Nelson; J Jensen; I Gigli; N Tamura
Journal:  Immunochemistry       Date:  1966-03

8.  The enzymatic nature of C'1r. Conversion of C'1s to C'1 esterase and digestion of amino acid esters by C'1r.

Authors:  G B Naff; O S Ratnoff
Journal:  J Exp Med       Date:  1968-10-01       Impact factor: 14.307

9.  The inhibition of plasmin, plasma kallikrein, plasma permeability factor, and the C'1r subcomponent of the first component of complement by serum C'1 esterase inhibitor.

Authors:  O D Ratnoff; J Pensky; D Ogston; G B Naff
Journal:  J Exp Med       Date:  1969-02-01       Impact factor: 14.307

10.  Release of kallikrein from guinea pig lung during anaphylaxis.

Authors:  O Jonasson; E L Becker
Journal:  J Exp Med       Date:  1966-03-01       Impact factor: 14.307

View more
  5 in total

1.  Studies on cell motility in inflammation. II. The in vivo effect of anti-inflammatory and anti-rheumatic drugs on chemotaxis in vitro.

Authors:  L Parente; M S Koh; D A Willoughby; A Kitchen
Journal:  Agents Actions       Date:  1979-06

2.  The role of kallikrein in leukocyte migration inhibition.

Authors:  A M Sultan; C J Dunn; D A Willoughby
Journal:  Inflammation       Date:  1979-07       Impact factor: 4.092

Review 3.  Acute inflammation. A review.

Authors:  G B Ryan; G Majno
Journal:  Am J Pathol       Date:  1977-01       Impact factor: 4.307

4.  Mechanisms of activation of the classical pathway of complement by Hageman factor fragment.

Authors:  B Ghebrehiwet; B P Randazzo; J T Dunn; M Silverberg; A P Kaplan
Journal:  J Clin Invest       Date:  1983-05       Impact factor: 14.808

5.  C3 proactivator convertase and its mode of action.

Authors:  H J Müller-Eberhard; O Götze
Journal:  J Exp Med       Date:  1972-04-01       Impact factor: 14.307

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.